Research Paper Volume 16, Issue 5 pp 4811—4831
FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway
Figure 7. FHND004 targets PBK leading to the inhibition of ERK1/2 phosphorylation in the MAPK pathway. (A, B) WB validated the protein expression profiles of ERK1/2 and p-ERK1/2 in PBK-WT and PBK-OE cells with or without treatment of FHND004 (4 μM) (A: ARP1, B: H929). n = 3. (C) Co-IP assay revealed that FHND004 (4 μM) interfered with the interaction between PBK and p-ERK1/2 in H929 PBK-OE cells. (D) Schematic diagram of the mechanism of FHND004 targeting PBK in MM.